Pentoxifylline therapy and method of use
First Claim
Patent Images
1. A dosage form for delivering pentoxifylline to a patient, the dosage form comprising:
- (a) a wall comprising a semipermeable composition permeable to the passage of fluid and substantially impermeable to the passage of pentoxifylline;
(b) a compartment defined by the wall;
(c) 10 ng to 750 mg of pentoxifylline in the compartment;
(d) an exit in the dosage form for the continuous release of pentoxifylline at a rate of 1 ng/hr to 30 mg/hr over an extended time of 24 hrs.
0 Assignments
0 Petitions
Accused Products
Abstract
A dosage form is disclosed for delivering pentoxifylline to a patient in need of pentoxifylline therapy. A method is discussed for delivery pentoxifylline to a patient at a dosage form controlled rate over an extended period of time.
29 Citations
7 Claims
-
1. A dosage form for delivering pentoxifylline to a patient, the dosage form comprising:
-
(a) a wall comprising a semipermeable composition permeable to the passage of fluid and substantially impermeable to the passage of pentoxifylline; (b) a compartment defined by the wall; (c) 10 ng to 750 mg of pentoxifylline in the compartment; (d) an exit in the dosage form for the continuous release of pentoxifylline at a rate of 1 ng/hr to 30 mg/hr over an extended time of 24 hrs.
-
-
2. A dosage form for the continuous delivery of pentoxifylline to a patient, wherein the dosage form comprises:
-
(a) a wall comprising a semipermeable composition permeable to the flux of fluid and substantially impermeable to the flux of pentoxifylline; (b) a compartment defined by the wall; (c) a pentoxifylline layer in the compartment comprising 100 ng to 750 mg of pentoxifylline; (d) a displacement layer in the compartment for the continuous-displacement of pentoxifylline from the dosage form; and
release of pentoxifylline at a rate of 1 ng/hr to 30 mg/hr over an extended time of 24 hrs;(e) an exit in the dosage form for the continuous-release of pentoxifylline over time.
-
-
3. A method for administering pentoxifylline to a patient in need of pentoxifylline, wherein the method comprises admitting into the patient a bioerodible-medicated dosage form comprising 100 ng to 750 mg of pentoxifylline in a bioerodible matrix that is continuously-administered at a rate of 1 ng/hr to 30 mg/hr controlled by the bioeroding matrix over an extended time up to 24 hours.
-
4. A method for administering pentoxifylline to a patient, wherein the method comprises:
-
(a) admitting into the patient a dosage form comprising; (1) a pentoxifylline composition comprising 100 ng to 750 mg of pentoxifylline; (2) a semipermeable wall that surrounds the pentoxifylline composition; (3) exit means in the dosage form for delivering pentoxifylline from the dosage form; (b) imbibing fluid into the dosage form causing the pentoxifylline composition to become deliverable from the dosage form; and
thereby,(c) administering the pentoxifylline at a continuous-rate of 1 ng to 50 mg per hour to the patient for pentoxifylline therapy.
-
-
5. A method for administering pentoxifylline to a patient, where in the method comprises:
-
(a) admitting into the patient a dosage form comprising; (1) a pentoxifylline composition comprising 100 ng to 750 mg of pentoxifylline; (2) a displacement composition that imbibes fluid and expands; (3) a semipermeable wall that surrounds (1) and (2); (4) an exit in the dosage form that connects the exterior of the dosage form with the pentoxifylline composition; (b) imbibing fluid into the dosage causing the displacement composition to expand and cooperate with the pentoxifylline composition for delivering the pentoxifylline composition through the exit; and
thereby(c) administering pentoxifylline to the patient for producing pentoxifylline therapy. - View Dependent Claims (6)
-
-
7. A method for administering pentoxifylline to a patient in need of pentoxifylline therapy, wherein the method comprises admitting orally into the patient a diffusion-mediated dosage form comprising up to 750 mg of pentoxifylline that is administered by a pentoxifylline releasing diffusion polymers at a sustained and controlled rate of 1 ng/hr to 30 mg/hr over 24 hours to provide the patient with pentoxifylline therapy.
Specification